Vergelijking

Icatibant vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

138614-30-9

396091-73-9

Molecuulmassa

1304.52 g/mol

1047.21 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Icatibant	Pasireotid
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Icatibant

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Icatibant and Pasireotid?: Icatibant is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Pasireotid?: The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Pasireotid in Germany and the United States?: Duitsland: Icatibant — Op recept, Pasireotid — Op recept. Verenigde Staten: Icatibant — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Pasireotid

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Icatibant and Pasireotid?

Icatibant is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Pasireotid?

The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Pasireotid in Germany and the United States?

Duitsland: Icatibant — Op recept, Pasireotid — Op recept. Verenigde Staten: Icatibant — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.